Ferring joins with UCB to promote CIMZIA prefilled syringe for Crohn’s disease in the United States. Co-promotion strengthens commitment to patients living with Crohn’s disease by reaching more gastroenterologists while also continuing patient support programs.
Lead Product(s): Certolizumab Pegol
Therapeutic Area: Gastroenterology Product Name: Cimzia
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: UCB Pharma S.A
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 08, 2020